Список литературы

1. Детская ревматология. Атлас. 2-е издание. Под ред. А.А. Баранова, Е.И. Алексеевой. Москва: ПедиатрЪ. 2015. С. 66 - 69.

2. Bartels CM. Systemic Lupus Erythematosus (SLE). URL: http://www.medscape.com. 2013. http://emedicine.medscape.com/article/332244-overview.

3. Bertsias G, loannidis JPA, Boletis J. et al. EULAR recommendations for the management of systemic lupus erythematosus. Report of a Task Force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics. Ann Rheum Dis. 2008; 67: 195 - 205.

4. Gokce M, Bilginer Y, Besbas N. et al. Hematological features of pediatric systemic lupus erythematosus: suggesting man agement strategies in children. Lupus. 2012; 21: 878-84.

5. Gurevitz SL, Snyder JA, Wessel EK. et al. Systemic lupus erythematosus: a review of the disease and treatment options. Consult Pharm. 2013; 28: 110-21.

6. Hahn BH, McMahon MA, Wilkinson A. et al. American College of Rheumatology guidelines for screening, treatment, and management of lupus nephritis. Arthritis Care Res (Hoboken). 2012; 64: 797 - 808

7. Klein-Gitelman MS. Pediatric Systemic Lupus Erythematosus. URL: http://www.medscape.com. 2013. http://emedicine.medscape.com/article/1008066-overview.

8. Merrill JT, Neuwelt CM, Wallace DJ. et al. Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II/III systemic lupus erythematosus evaluation of rituximabtrial. Arthritis Rheum. 2010; 62: 222-33.

9. Murdaca G, Orsi A, Spano F. et al. Influenza and pneumococcal vaccinations of patients with systemic lupus erythematosus: current views upon safety and immunogenicity. Autoimmun Rev. 2014; 13: 75.

10. Petty RE, Laxer RM, Lindsley CB. et al. Textbook of pediatric rheumatology. 5th edn. Elsevier Saunders, Philadelphia. 2016.

11. Rovin BH, Furie R, Latinis K. et al. Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the Lupus Nephritis Assessment with Rituximab study. Arthritis Rheum. 2012; 64: 1215-26.

12. Trachana M, Koutsonikoli A, Farmaki E. et al. Safety and efficacy of rituximab in refractory pediatric systemic lupus erythemato sus nephritis: a single-center experience of Northern Greece. Rheumatol Int. 2013; 33: 809-13.

13. Wallace DJ. Quality guidelines for systemic lupus erythematosus: slow but steady progress. J Rheumatol. 2013; 40: 542-3.

14. Wallace DJ, Hahn BH, Elsevier. Dubois" lupus erythematosus and related syndromes. 8th ed. Philadelphia, Elsevier. Saun ders. 2013.

15. van Vollenhoven RF, Mosca M, Bertsias G. et al. Treat-to-target in systemic lupus erythematosus: recommendations from an international task force. Ann Rheum Dis. 2014; 73: 958.

16. Yeung KS1, Chung BH1, Choufani S2, Mok MY3,4, Wong WL1, Mak CC1, Yang W1, Lee PP1, Wong WH1, Chen YA2, Grafodatskaya D2, Wong RW3, Lau CS3, Chan DT3, Weksberg R2,5,6, Lau YL1.

17. Genome-Wide DNA Methylation Analysis of Chinese Patients with Systemic Lupus ErythematosusIdentified Hypomethylation in Genes Related to the Type I Interferon Pathway. PLoS One. 2017 Jan 13; 12(1): e0169553. doi: 10.1371/journal.pone.0169553.eCollection 2017.

18. Ragotte RJ1, Dhanrajani A1, Pleydell-Pearce J2, Del Bel KL1, Tarailo-Graovac M3, van Karnebeek C3, Terry J4, Senger C4, McKinnon ML3, Seear M1, Prendiville JS1, Tucker LB1, Houghton K1, Cabral DA1, Guzman J1, Petty RE1, Brown KL1, Tekano J1, Wu J1, Morishita KA5, Turvey SE6. The importance of considering monogenic causes of autoimmunity: A somatic mutation in KRAS causing pediatric Rosai-Dorfman syndrome and systemic lupus erythematosus. ClinImmunol. 2016 Dec 31. pii: S1521-6616(16) 30507-1. doi: 10.1016/j.clim.2016.12.006. [Epub ahead of print]

19. Thong B1, Olsen NJ2. Systemic lupus erythematosus diagnosis and management. Rheumatology (Oxford). 2016 Dec 24. pii: kew401. doi: 10.1093/rheumatology/kew401. [Epub ahead of print]

20. Fatemi A1, Matinfar M2, Smiley A3. Childhood versus adult-onset systemic lupus erythematosus: long-term outcome and predictors of mortality. Clin Rheumatol. 2016 Dec 23. doi: 10.1007/s10067-016-3509-1. [Epub ahead of print]

21. Prabha R1, Mathew BS1, Jeyaseelan V2, Kumar TS3, Agarwal I3, Fleming DH1. Development and validation of limited sampling strategy equation for mycophenolate mofetil in childrenwith systemic lupus erythematosus. Indian J Nephrol. 2016 Nov-Dec; 26(6): 408 - 412.

22. Wakiguchi H1,2, Takei S3,4, Kubota T3, Miyazono A3, Kawano Y3. Treatable renal disease in children with silent lupus nephritis detected by baseline biopsy: association with serum C3 levels. Clin Rheumatol. 2016 Nov 30. [Epub ahead of print]

23. Pinto AJ1, Miyake CN1, Benatti FB1, Silva CA1, Sallum AM1, Borba E1, de AL1, E1, Gualano B1. Reduced Aerobic Capacity and Quality of Life in Physically Inactive Patients With Systemic Lupus Erythematosus With Mild or Inactive Disease. Arthritis Care Res (Hoboken). 2016 Dec; 68(12): 1780 - 1786. doi: 10.1002/acr.22905. Epub 2016 Oct 28.

24. Thakral A1, Klein-Gitelman MS2. An Update on Treatment and Management of Pediatric Systemic Lupus Erythematosus. Rheumatol Ther. 2016 Dec; 3(2): 209 - 219. Epub 2016 Sep 30.